Lopinavir European Pharmacopeia HPLC Assay Method

Anita Piper


This paper illustrates how it is possible to set-up the assay method for Lopinavir testing following the current European pharmacopeia guidelines (10.2). The monograph assay method calls for a column with l = 0.25 m, Ø = 4.6 mm end-capped octadecylsilyl silica gel for chromatography with 4 µm particle size. No particular HPLC column is referenced in the EP knowledge database for assay method, and the method is of isocratic nature.

This gives a chance to replace the monograph column geometry/particle size with a shorter and faster alternative column (up to 70% reduction in length) packed with smaller particles (up to 50% reduction). This can save valuable time, and at the same time you can benefit from improved separation efficiency, which typically translates into better method performance and sensitivity. In this study, the limit of detection (LOD) is better than 1 ppm using HPLC-UV detection.


Figure 1. Lopinavir

Reference Solution (a)

Figure 2. Reference Solution (a)

Test Solution (b)

Figure 3. Test Solution (b)

Specificity: Inject reference solution (a) and determine the retention time and the content of desired analyte.

Standard Repeatability (25 ppm)



Figure 4. Concentration


In this study in reference to European Pharmacopeia 10 Guidelines, a shorter and faster Fused-Core® (Superficially Porous Particle, SPP) column was evaluated for an assay method for Lopinavir, achieving a limit of detection (LOD) of better than 1 ppm using HPLC-UV detection.


Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.